Evidence map›Paper›PMID 38274721›Full record

ArticleWorld journal of oncology2024

Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line, ICC-X2.

Hao Xu, Chang Peng Chai, Huan Tang, Yuan Hui Su, Cheng Yu, Lu Li, Jian Feng Yi, Zhen Zhen Ye, Zheng Feng Wang, Jin Jing Hu and 4 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Hao XuThe Fourth Department of General Surgery, the First Hospital of Lanzhou University, Lanzhou 730000, China.
Chang Peng ChaiThe Fourth Department of General Surgery, the First Hospital of Lanzhou University, Lanzhou 730000, China.
Huan TangThe Second Clinical Medical College, Lanzhou University, Lanzhou 730000, China.
Yuan Hui SuThe Second Clinical Medical College, Lanzhou University, Lanzhou 730000, China.
Cheng YuThe Second Clinical Medical College, Lanzhou University, Lanzhou 730000, China.
Lu LiThe Fourth Department of General Surgery, the First Hospital of Lanzhou University, Lanzhou 730000, China.
Jian Feng YiThe First Clinical Medical College, Lanzhou University, Lanzhou 730000, China.
Zhen Zhen YeThe Second Clinical Medical College, Lanzhou University, Lanzhou 730000, China.
Zheng Feng WangThe Fourth Department of General Surgery, the First Hospital of Lanzhou University, Lanzhou 730000, China.
Jin Jing HuThe Fourth Department of General Surgery, the First Hospital of Lanzhou University, Lanzhou 730000, China.
Wei LuoThe Fourth Department of General Surgery, the First Hospital of Lanzhou University, Lanzhou 730000, China.
Hui ZhangThe Second Clinical Medical College, Lanzhou University, Lanzhou 730000, China.
Xin MiaoState Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Animal Virology of the Ministry of Agriculture, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730000, China.ORCID https://orcid.org/0009-0005-4319-2107
Wen Ce ZhouThe Second Clinical Medical College, Lanzhou University, Lanzhou 730000, China.ORCID https://orcid.org/0000-0002-0529-7777
Lanzhou University Second Hospital · CNFirst Hospital of Lanzhou University · CNGansu University of Traditional Chinese Medicine · CNLanzhou Veterinary Research Institute · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Intrahepatic cholangiocarcinoma (ICC) is an aggressive malignant tumor of the biliary tract that is prone to recurrence and metastasis and is characterized by poor sensitivity to chemotherapy and overall prognosis. For these reasons, there is an urgent need to understand its pathological mechanisms and develop effective treatments. To address this challenge, the establishment of suitable preclinical models is critical. Methods: Fresh ICC tissue samples were used for primary culture and subculture. The cell line was evaluated by cell proliferation assays, clonal formation assays, karyotype analysis, and short tandem repeat (STR) analysis. Drug resistances against oxaliplatin, paclitaxel, gemcitabine and 5-fluorouracil (5-FU) were evaluated by CCK-8 assay. Subcutaneous injection of 1 × 10 Results: A new ICC cell line named ICC-X2 was successfully established. Like ICC-X3 established using the same patient's metastatic tumor, the cell line has been continuously cultured Conclusions: ICC-X2 is an excellent experimental model that can be used for studying the occurrence, development, and metastasis of ICC and investigating the mechanism of tumor drug resistance.

Indexed as

Animal modelCell lineEstablishmentIntrahepatic cholangiocarcinomaXenograft

Identifiers

PMID38274721
PMCPMC10807924
OpenAlexW4391041963

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.